The US Food & Drug Administration (FDA) has refused to give its approval to Motif Bio’s skin disorder drug iclaprim for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
15 Feb 2019
13 Feb 2019
FDA takes action against 17 firms for illegally selling products that claim to treat Alzheimer’s disease
The US Food and Drug Administration has posted 12 warning letters and 5 online advisory letters issued to foreign and domestic companies that are illegally selling more than 58 products, many that are sold as dietary supplements, which are unapproved new drugs and/or misbranded drugs that claim to prevent, treat or cure Alzheimer’s disease and a number of other serious diseases and health conditions.
26 Oct 2018
The US Food and Drug Administration has refused to approve Regeneron’s pre-filled syringe version of eye-drug Eylea (aflibercept).
10 Sep 2018
The US Food and Drug Administration (FDA) has refused to approve the use of GlaxoSmithKline’s mepolizumab for treating patients with chronic obstructive pulmonary disease (COPD) on grounds of needing more clinical data.
03 Sep 2018
Sunovion Pharmaceuticals has failed to get approval from the US Food and Drug Administration (FDA) for dasotraline to treat attention-deficit hyperactivity disorder (ADHD).
27 Jul 2018
The Pulmonary Allergy Drugs Advisory Committee of the US Food and Drug Administration (FDA) has voted against recommending GlaxoSmithKline’s (GSK) mepolizumab as an add-on treatment to inhaled corticosteroid-based maintenance treatment to reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD) guided by blood eosinophil counts.
17 May 2018
The US Food and Drug Administration (FDA) has declined to approve Evolus' application seeking approval of DWP-450 to treat glabellar lines in adult patients.
10 May 2018
The US Food and Drug Administration (FDA) has refused to approve Lipocine's Tlando, an oral testosterone product candidate for testosterone replacement therapy (TRT).
18 Jul 2017
The US Food and Drug Administration (FDA) has rejected Amgen and UCB’s biologics license application (BLA) for Evenity (romosozumab) to treat postmenopausal women with osteoporosis